Table 3 Frequencies of genetic polymorphisms according Remission or Persistence of pre-neoplastic cervical lesions
Genetic polymorphisms | Cytological abnormality | ||||
|---|---|---|---|---|---|
Total | Remission (n = 60) | Persistence (n = 46) | OR (IC95%)a | p | |
MTHFR C677T1 | |||||
Genotype n (%) | |||||
CC | 53 (50.0) | 28 (46.7) | 25 (54.3) | 1.0 | |
CT | 48 (45.3) | 28 (46.7) | 20 (43.5) | 0.93 (0.40–2.12) | 0.856 |
TT | 5 (2.2) | 4 (6.6) | 1 (2.2) | 0.25 (0.02–2.48) | 0.245 |
Allele % | |||||
C | 72.6 | 70.0 | 76.1 | 1.0 | |
T | 27.4 | 30.0 | 23.9 | 0.71 (0.34–2.11) | 0.842 |
MS A2756G2 | |||||
Genotype n (%) | |||||
AA | 69 (65.4) | 42 (70.0) | 27 (58.7) | 1.0 | |
AG | 33 (31.1) | 17 (28.3) | 16 (34.8) | 1.20 (0.50–2.89) | 0.690 |
GG | 4 (3.8) | 1 (1.7) | 3 (6.5) | 4.99 (0.46–54.57) | 0.188 |
Allele % | |||||
A | 80.2 | 83.3 | 76.1 | 1.0 | |
G | 19.8 | 16.7 | 23.9 | 1.63 (0.59–4.53) | 0.349 |
TS3’UTR3 | |||||
Genotype n (%) | |||||
ins/ins | 34 (32.1) | 26 (43.3) | 8 (17.4) | 1.0 | |
ins/del | 55 (51.9) | 28 (46.7) | 27 (58.7) | 3.22 (1.19–8.69) | 0.021 |
del/del | 17 (16.0) | 6 (10.0) | 11 (23.9) | 6.50 (1.71–24,70) | 0.006 |
Allele % | |||||
ins | 58.5 | 66.7 | 47.8 | 1.0 | |
del | 41.5 | 33.3 | 52.2 | 2.28 (1.00–5.22) | 0.051 |
GRS n(%) | |||||
≤ 2 | 77 (72.6) | 48 (80.0) | 29 (63.0) | 1.00 | |
≥ 3 | 29 (27.4) | 12 (20.0) | 17 (37.0) | 2.21 (0.89–5.48) | 0.086 |